NxStage Medical, Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 6,000 shares of the business’s stock in a transaction on Friday, February 17th. The stock was sold at an average price of $29.66, for a total value of $177,960.00. Following the completion of the transaction, the president now directly owns 75,280 shares of the company’s stock, valued at $2,232,804.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) opened at 29.10 on Friday. NxStage Medical, Inc. has a 12 month low of $13.49 and a 12 month high of $29.99. The stock has a 50 day moving average price of $27.62 and a 200-day moving average price of $25.25. The stock’s market cap is $1.88 billion.
“Insider Selling: NxStage Medical, Inc. (NXTM) President Sells $177,960.00 in Stock” was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/02/24/insider-selling-nxstage-medical-inc-nxtm-president-sells-177960-00-in-stock.html.
NXTM has been the subject of a number of recent analyst reports. Northland Securities set a $35.00 price objective on NxStage Medical and gave the company a “buy” rating in a research report on Friday, December 16th. Jefferies Group LLC lifted their price objective on NxStage Medical to $38.00 and gave the company a “buy” rating in a research report on Monday, February 6th. Canaccord Genuity set a $31.00 price objective on NxStage Medical and gave the company a “buy” rating in a research report on Monday, January 23rd. Finally, Zacks Investment Research raised NxStage Medical from a “hold” rating to a “strong-buy” rating and set a $24.00 price objective for the company in a research report on Thursday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. NxStage Medical has an average rating of “Buy” and an average target price of $29.67.
Institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas raised its position in shares of NxStage Medical by 35.5% in the second quarter. Teacher Retirement System of Texas now owns 8,958 shares of the medical device company’s stock worth $194,000 after buying an additional 2,347 shares during the last quarter. Essex Investment Management Co. LLC raised its position in shares of NxStage Medical by 68.5% in the third quarter. Essex Investment Management Co. LLC now owns 86,727 shares of the medical device company’s stock worth $2,167,000 after buying an additional 35,268 shares during the last quarter. First Trust Advisors LP purchased a new position in shares of NxStage Medical during the third quarter worth about $1,657,000. Oxford Asset Management raised its position in shares of NxStage Medical by 14.2% in the fourth quarter. Oxford Asset Management now owns 82,120 shares of the medical device company’s stock worth $2,152,000 after buying an additional 10,242 shares during the last quarter. Finally, BlackRock Group LTD raised its position in shares of NxStage Medical by 2.0% in the third quarter. BlackRock Group LTD now owns 75,478 shares of the medical device company’s stock worth $1,887,000 after buying an additional 1,458 shares during the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.